Priya Singhal - Jan 5, 2023 Form 3 Insider Report for BIOGEN INC. (BIIB)

Role: Head of Development
Signature: /s/ Wendell Taylor, attorney-in-fact for Priya Singhal
Stock symbol: BIIB
Transactions as of: Jan 5, 2023
Transactions value $: $0
Form type: 3
Date filed: 1/17/2023, 03:53 PM
Next filing: Jan 27, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	BIIB	Common Stock						1.53K	Jan 5, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BIIB	Restricted Stock Unit							Jan 5, 2023	Common Stock	1.74K	$0.00	Direct	F1
holding	BIIB	Restricted Stock Unit							Jan 5, 2023	Common Stock	638	$0.00	Direct	F2
holding	BIIB	Restricted Stock Unit							Jan 5, 2023	Common Stock	852	$0.00	Direct	F3
holding	BIIB	Restricted Stock Unit							Jan 5, 2023	Common Stock	3.64K	$0.00	Direct	F4
holding	BIIB	Restricted Stock Unit							Jan 5, 2023	Common Stock	315	$0.00	Direct	F5
holding	BIIB	Restricted Stock Unit							Jan 5, 2023	Common Stock	5.01K	$0.00	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This award was granted to the reporting person on February 18, 2021. The number of Restricted Stock Units ("RSUs") reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F2	This award was granted to the reporting person on March 2, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F3	This award was granted to the reporting person on December 8, 2021 and will vest in three equal installments on each anniversary of the grant date.
F4	This award was granted to the reporting person on February 10, 2022 and will vest in three equal installments on each anniversary of the grant date.
F5	This award was granted to the reporting person on July 1, 2020 and will vest in three equal installments on each anniversary of the grant date.
F6	This award was granted to the reporting person on September 1, 2022 and will vest in three equal installments on each anniversary of the grant date.